Literature DB >> 31280231

Chemoradiotherapy for Local Recurrence of Rectal Cancer: A Single Center Study of 18 Patients.

Junko Watanabe1, Hirokazu Shoji2, Tetsuya Hamaguchi1,3, Takahiro Miyamoto1, Hidekazu Hirano1, Satoru Iwasa1, Yoshitaka Honma1, Atsuo Takashima1, Ken Kato1, Yoshinori Ito4,5, Jun Itami4, Yukihide Kanemitsu6, Narikazu Boku1.   

Abstract

BACKGROUND/AIM: When possible, surgical resection is recommended for local recurrence after resection of colorectal cancer. In unresectable cases, chemotherapy is usually indicated, although the success of chemoradiotherapy (CRT) in this setting is unclear. PATIENTS AND METHODS: We retrospectively reviewed the treatment outcomes of 18 patients who received CRT for unresectable local recurrence after radical colorectal cancer surgery at our hospital between January 2000 and May 2016.
RESULTS: Of these 18 patients, three experienced complete response and four experienced partial response, resulting in a 39% overall response. With a median follow-up time of 42 months, the 5-year progression-free survival and overall survival were 34.8% and 54.4%, respectively; associated with a median local failure-free survival time of 40.9 months. Two of the three patients that underwent CRT remained local failure free for 5 years.
CONCLUSION: CRT for local recurrence of rectal cancer without distant metastasis produces similar overall survival rates and local control as conventional surgical resection. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Rectal cancer; chemoradiotherapy; local recurrence

Year:  2019        PMID: 31280231      PMCID: PMC6689370          DOI: 10.21873/invivo.11612

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  1 in total

1.  Efficacy and safety of radiotherapy combined with raltitrexed and irinotecan for treating unresectable recurrent colorectal cancer: a single-arm phase II trial.

Authors:  Xinghui Li; Jinwen Shen; Fan Xia; Ji Zhu
Journal:  J Gastrointest Oncol       Date:  2022-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.